MANNKIND CORP Long-Term Debt, Maturity, Year Five
MANNKIND CORP (MNKD) had Long-Term Debt, Maturity, Year Five of $75.00 million as of 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2025-11-05
- 2025-09-30: Long-Term Debt, Maturity, Year Five $75.00M.
- 2020-03-31: Long-Term Debt, Maturity, Year Five $83.94M.
- 2019-12-31: Long-Term Debt, Maturity, Year Five $83.94M.
- 2014-12-31: Long-Term Debt, Maturity, Year Five $35.00M.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2025-09-30 | $75.00M 10-Q · filed 2025-11-05 |
| 2020-03-31 | $83.94M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $83.94M 10-K · filed 2020-02-25 |
| 2014-12-31 | $35.00M 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |